CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs
Authors
Keywords
-
Journal
JOURNAL OF HEADACHE AND PAIN
Volume 22, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-10-25
DOI
10.1186/s10194-021-01335-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Randomised, controlled trial of erenumab for the prevention of episodic migraine in patients from Asia, the Middle East, and Latin America: The EMPOwER study
- (2021) Shuu-Jiun Wang et al. CEPHALALGIA
- Efficacy and safety of fremanezumab for episodic migraine prevention: Multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group trial in Japanese and Korean patients
- (2021) Fumihiko Sakai et al. HEADACHE
- Efficacy and safety of fremanezumab for chronic migraine prevention: Multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group trial in Japanese and Korean patients
- (2021) Fumihiko Sakai et al. HEADACHE
- Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1)
- (2020) Messoud Ashina et al. CEPHALALGIA
- Efficacy and safety of eptinezumab in patients with chronic migraine
- (2020) Richard B. Lipton et al. NEUROLOGY
- Monoclonal antibodies as a preventive therapy for migraine: A meta-analysis
- (2020) Yousef Waleed Alasad et al. CLINICAL NEUROLOGY AND NEUROSURGERY
- Efficacy and Contextual (Placebo) Effects of CGRP Antibodies for Migraine: Systematic Review and Meta‐analysis
- (2020) Raeburn B. Forbes et al. HEADACHE
- Monoclonal antibodies blocking CGRP transmission: An update on their added value in migraine prevention
- (2020) J. Schoenen et al. REVUE NEUROLOGIQUE
- The relation between the placebo response, observed treatment effect, and failure to meet primary endpoint: A systematic review of clinical trials of preventative pharmacological migraine treatments
- (2020) Kathryn Evans et al. CEPHALALGIA
- Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial
- (2020) Wim M Mulleners et al. LANCET NEUROLOGY
- European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention
- (2019) Simona Sacco et al. JOURNAL OF HEADACHE AND PAIN
- CGRP monoclonal antibody for preventive treatment of chronic migraine: An update of meta-analysis
- (2019) Lin Han et al. Brain and Behavior
- Eptinezumab for prevention of chronic migraine: A randomized phase 2b clinical trial
- (2019) David W Dodick et al. CEPHALALGIA
- Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial
- (2019) Michel D Ferrari et al. LANCET
- A Randomized Phase 2 Study of Erenumab for the Prevention of Episodic Migraine in Japanese Adults
- (2019) Fumihiko Sakai et al. HEADACHE
- Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial
- (2018) Vladimir Skljarevski et al. CEPHALALGIA
- ARISE: A Phase 3 randomized trial of erenumab for episodic migraine
- (2018) David W Dodick et al. CEPHALALGIA
- A Review of Monoclonal Antibody Therapies and Other Preventative Treatments in Migraine
- (2018) Uwe Reuter HEADACHE
- Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine
- (2018) David W. Dodick et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- CGRP as the target of new migraine therapies — successful translation from bench to clinic
- (2018) Lars Edvinsson et al. Nature Reviews Neurology
- Evaluation of Galcanezumab for the Prevention of Episodic Migraine
- (2018) Virginia L. Stauffer et al. JAMA Neurology
- Effect of Different Doses of Galcanezumab vs Placebo for Episodic Migraine Prevention
- (2018) Vladimir Skljarevski et al. JAMA Neurology
- The efficacy and safety of calcitonin gene-related peptide monoclonal antibody for episodic migraine: a meta-analysis
- (2018) Yuhan Zhu et al. NEUROLOGICAL SCIENCES
- Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study
- (2018) Uwe Reuter et al. LANCET
- Galcanezumab in chronic migraine
- (2018) Holland C. Detke et al. NEUROLOGY
- Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial
- (2017) Stewart Tepper et al. LANCET NEUROLOGY
- Fremanezumab for the Preventive Treatment of Chronic Migraine
- (2017) Stephen D. Silberstein et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Controlled Trial of Erenumab for Episodic Migraine
- (2017) Peter J. Goadsby et al. NEW ENGLAND JOURNAL OF MEDICINE
- Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: A retrospective claims analysis
- (2016) Zsolt Hepp et al. CEPHALALGIA
- Randomised clinical trial comparing melatonin 3 mg, amitriptyline 25 mg and placebo for migraine prevention
- (2016) Andre Leite Gonçalves et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial
- (2016) Hong Sun et al. LANCET NEUROLOGY
- Systematic Review of Migraine Prophylaxis Adherence and Persistence
- (2016) Zsolt Hepp et al. JOURNAL OF MANAGED CARE PHARMACY
- Drug safety and tolerability in prophylactic migraine treatment
- (2015) László Vécsei et al. Expert Opinion On Drug Safety
- Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study
- (2015) Marcelo E Bigal et al. LANCET NEUROLOGY
- Antiepileptics in migraine prophylaxis: An updated Cochrane review
- (2014) Wim M Mulleners et al. CEPHALALGIA
- Adherence to oral migraine-preventive medications among patients with chronic migraine
- (2014) Zsolt Hepp et al. CEPHALALGIA
- Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study
- (2014) David W Dodick et al. LANCET NEUROLOGY
- Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial
- (2014) David W Dodick et al. LANCET NEUROLOGY
- A comparative study of candesartan versus propranolol for migraine prophylaxis: A randomised, triple-blind, placebo-controlled, double cross-over study
- (2013) Lars J Stovner et al. CEPHALALGIA
- Patterns of Use and Reasons for Discontinuation of Prophylactic Medications for Episodic Migraine and Chronic Migraine: Results From the Second International Burden of Migraine Study (IBMS-II)
- (2013) Andrew M. Blumenfeld et al. HEADACHE
- Guidelines for controlled trials of drugs in migraine: Third edition. A guide for investigators
- (2012) et al. CEPHALALGIA
- Evidence-based guideline update: Pharmacologic treatment for episodic migraine prevention in adults: Table 1
- (2012) S.D. Silberstein et al. NEUROLOGY
- Topiramate intervention to prevent transformation of episodic migraine: The topiramate INTREPID study
- (2010) Richard B Lipton et al. CEPHALALGIA
- OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial
- (2010) SK Aurora et al. CEPHALALGIA
- OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial
- (2010) HC Diener et al. CEPHALALGIA
- Amitriptyline in the Prophylactic Treatment of Migraine and Chronic Daily Headache
- (2010) James R. Couch et al. HEADACHE
- OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Results From the Double-Blind, Randomized, Placebo-Controlled Phases of the PREEMPT Clinical Program
- (2010) David W. Dodick et al. HEADACHE
- EFNS guideline on the drug treatment of migraine - revised report of an EFNS task force
- (2009) S. Evers et al. EUROPEAN JOURNAL OF NEUROLOGY
- Effects of topiramate and levetiracetam vs placebo on habituation of contingent negative variation in migraine patients
- (2008) Marina de Tommaso et al. NEUROSCIENCE LETTERS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More